INTRODUCTION
Mast cells (MCs) are key effector cells in allergic conditions such as asthma but they are also regarded as regulatory cells, fine-tuning immune responses in various ways. 1 When MCs are activated, they may degranulate and thereby release a number of preformed compounds from their secretory granules, including bioactive amines, cytokines, proteoglycans, and various MC-specific proteases, the latter encompassing chymases, tryptases, and carboxypeptidase A3. 2, 3 Activated MCs may also respond by de novo synthesis of additional proinflammatory compounds. 4 The MC proteases constitute a major part of the total content of the MC granules. Hence, large amounts of proteases are released upon MC degranulation, and it is likely that they will have a major impact on any condition in which MC degranulation occurs. 3 Out of the various murine chymases, mouse mast cell protease 4 (mMCP-4) is considered to be the functional counterpart to the single human chymase. 3, 5 In a recent study, we showed that mMCP-4 has protective properties in an acute model of allergic airway inflammation induced by intraperitoneal sensitization followed by intranasal challenge with ovalbumin (OVA). 6 However, the exact mechanism by which mMCP-4 dampens airway responses is not known. Moreover, it is important to emphasize that the OVA model has been questioned in terms of relevance for human asthma. 7, 8 The aim of this investigation was therefore to investigate the role of chymase in a physiologically relevant model for asthma, and also to address the mechanism by which chymase influences airway responses.
House-dust mite (HDM) is a prevalent allergen of humans and is a major cause of human asthma. 9 HDM-induced allergic airway inflammation in mice shares many of the features of human asthma, including upregulated T helper type 2 (Th2) cytokines and immunoglobulin E (IgE) synthesis, lung eosinophilia, and airway hyperresponsiveness and is therefore emerging as a physiologically relevant model for human asthma.
smooth muscle (ASM) thickening, and elevated airway reactivity at high doses of metacholine, indicating a protective role for MC chymase. Further, our data suggest that the protective function of chymase mechanistically can be linked to effects on interleukin (IL)-33.
RESULTS mMCP-4 reduces airway reactivity
To investigate the role of mMCP-4 in HDM-induced allergic airway inflammation, we used mMCP-4 À / À mice 5 and wildtype (WT) controls. Mice received intranasal doses of HDM extract twice weekly for 3 weeks. Invasive lung mechanics measurements were performed 48 h after the last challenge. HDM-treated WT and mMCP-4 À / À mice both exhibited increased airway reactivity in response to inhaled methacholine as compared with phosphate-buffered saline (PBS)-treated controls ( Figure 1a) . However, the airway reactivity was augmented in mMCP-4 À / À mice as compared with WT controls at the highest dose of metacholine used (Figure 1a) , suggesting that MC chymase has a protective role by preventing excessive airway reactivity. There were no differences, regardless of treatment or genotype, in number of MCs in the lung, as determined by toluidine blue staining (Supplementary Figure S1 The magnitude of the inflammatory response can be estimated by the number of inflammatory cells recruited into the tissue. Hence, we next characterized the inflammatory cells in BAL fluid. HDM-treated mice contained significantly higher number of total cells compared with untreated controls (Figure 1b) . The increase in total cell numbers was predominantly reflected by a massive increase in BAL eosinophils ( Figure 1c ). Significant increases in BAL lymphocytes and neutrophils were also observed, whereas the BAL macrophage population was not affected (Figure 1d-f ).
In accordance with a protective role of chymase, higher total numbers of cells were seen in BAL fluid from HDM-treated mMCP-4 À / À as compared with WT mice (Figure 1b) . This was predominantly explained by effects on eosinophils, with Bfivefold higher numbers of eosinophils found in BAL fluid from HDM-treated mMCP-4 À / À mice than in WT controls ( Figure 1c) . To further assess the role of mMCP-4 in regulating airway responses, we analyzed the lung tissue sections for signs of inflammation. As shown in Figure 2a ,b, HDM treatment induced tissue inflammation in the perivascular and peribronchial areas, the inflammatory infiltrate mainly being composed of eosinophils. In line with a protective role of chymase, HDM-instilled mMCP-4 À / À mice exhibited significantly higher numbers of tissue eosinophils ( Figure 2c) and percentage of bronchioles surrounded with cell infiltrates (Figure 2d ) than did WT controls. Next, we investigated effects on the ASM layer of the bronchi. No baseline difference in the thickness of the ASM layer was seen when comparing PBStreated WT and mMCP-4 À / À mice ( Figure 2e ). When WT mice were treated with HDM, there was a statistically nonsignificant trend towards increased ASM thickening. By striking contrast, HDM-treatment of mMCP-4 À / À mice caused a profoundly increased thickening of the ASM layer compared with PBS-treated controls (Figure 2e) . Hence, chymase protects against remodeling events leading to extensive thickening of the ASM layer in response to HDM. Periodic acid-Schiff staining of the lung tissue sections revealed occasional goblet cells in airways of PBStreated mice, whereas after instillations with HDM extract, goblet cells were highly abundant (Figure 2f) . However, there was no difference in the degree of goblet cell metaplasia when comparing HDM-treated WT and mMCP-4 À / À mice ( Figure 2f ).
mMCP-4 regulates the IgE response
The data above indicate that mMCP-4 has an impact on the late inflammatory phase of the allergic lung disease. However, as mMCP-4-positive MCs constitute a resident cell population of the lung, 6 it is conceivable that mMCP-4 can encounter HDM antigen at an early stage of the response, thereby potentially influencing the sensitization phase leading to IgE production. To address this possibility, we tested whether the absence of mMCP-4 affects the levels of serum IgE upon HDM treatment. As expected, serum IgE levels were significantly increased in HDM-treated WT mice as compared with non-treated control animals ( Figure 3a) . Moreover, sensitized mMCP-4 À / À mice displayed significantly higher serum IgE levels as compared with WT mice (Figure 3a) . These results suggest a regulatory role for mMCP-4 in the early sensitization process.
mMCP-4 affects cytokine release after restimulation of splenocytes
To further address the possibility that mMCP-4 affects the sensitization towards HDM antigens, we assessed whether mMCP-4 can influence the HDM-specific cytokine response. To this end, single-cell suspensions of splenocytes were restimulated with HDM extract followed by measurements of IL-13, IL-17A, and IL-6 release. As shown in Figure 3b , splenocytes from HDM-treated mMCP-4 À / À mice secreted higher levels of IL-13 upon HDM restimulation than did cells from WT mice. It is also notable that the extent of IL-13 secretion by HDM-restimulated splenocytes correlated significantly with the number of BAL cells (Figure 3c) . Moreover, as shown in Figure 3d , the IL-17A response was significantly higher in splenocytes from HDM-treated mMCP-4 À / À mice vs. WT counterparts. By contrast, the absence of mMCP-4 did not have any effects on the secretion of IL-6 ( Figure 3e ). Together, these data indicate that mMCP-4 influences the activation state of the T lymphocyte populations reactive to HDM.
HDM extract induces MC degranulation and chymase release
The data above suggest that chymase, in addition to influencing the late inflammatory phase of an airway reaction, also may have effects on the sensitization phase. In turn, this implies that chymase may be released independently of crosslinking of HDM-specific IgE bound to the high affinity IgE receptors on the MC surface, e.g., through direct effects of the HDM extract on MCs. To evaluate this possibility, we determined whether HDM extract could directly induce MC degranulation leading to release of chymase. Indeed, exposure of peritoneal cell-derived MCs (PCMCs) 12 to HDM extract caused significant release of both b-hexosaminidase and histamine into the supernatant, with no difference seen between WT and mMCP-4 To search for mechanisms explaining the protective function of chymase in airway reactions, we evaluated the possibility that chymase acts by regulating the levels of the pro-inflammatory Th2 cytokines IL-5, IL-13, thymic stromal lymphopoietin (TSLP), and IL-33, all of these cytokines being known to be of importance in the development of allergic lung disease. 9, 10 As shown in Figure 5a -c, there were no differences in the levels of IL-5, IL-13, or TSLP in the lung tissue homogenates from WT To search for the mechanism underlying the IL-33 accumulation, we evaluated the possibility that MC proteases could reduce IL-33 levels by proteolytic cleavage. To address this, we investigated the ability of WT and mMCP-4
PCMCs to reduce IL-33 levels. As shown in Figure 6a , IL-33 levels were rapidly reduced by MCs activated by IgE receptor crosslinking and this effect was completely blocked by a serine protease inhibitor, suggesting that the reduction of IL-33 was due to proteolytic degradation. Moreover, the effects on IL-33 were significantly diminished in cultures of mMCP-4 in the process. To provide direct evidence for proteolytic effects of chymase on IL-33, recombinant murine and human IL-33 was incubated with purified mMCP-4 and human chymase, respectively, followed by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis. Indeed, both mMCP-4 and human chymase caused rapid and extensive degradation of IL-33, thus confirming that IL-33 is a good substrate for MC chymase (Figure 6b) . IL-33 degradation was abrogated when mMCP-4 was pre-incubated with Pefabloc SC, a general serine protease inhibitor, verifying that the observed IL-33 reduction is due to proteolysis. 
DISCUSSION
Here we show that chymase, i.e., one of the major compounds secreted by activated MCs, has a major impact on HDMinduced allergic airway responses. Intriguingly, although both clinical evidence and work based on mouse models for asthma support an overall detrimental role for MCs in conjunction with asthma, [13] [14] [15] [16] [17] we here demonstrate a protective role of one of the compounds secreted by activated MCs, i.e., chymase. This finding is in line with a previous study where we showed that chymase has a protective function in a model where allergic airway inflammation was induced using an OVAbased protocol, 6 and also in line with previous findings showing that MC proteases, including chymase, can degrade pathogenic cytokines. [18] [19] [20] [21] [22] In further support for a protective role of chymase, there is clinical evidence showing a positive correlation between chymase-positive MCs and preserved lung function in severe asthma, 23, 24 and there is also clinical data suggesting that Th2-high asthma is associated with an intraepithelial MC phenotype with low chymase expression. 25 Collectively, these findings thus argue that MC chymase may have a general downregulatory effect on allergic airway responses, independently of species and independently of the regimen used for provoking the response. Possibly, this could serve as a regulatory mechanism that counteracts the otherwise detrimental actions of MCs (and/or other cell types). The net impact of MCs may thus be a result of a balance between detrimental and protective actions, mediated by distinct MC-related effector mechanisms. Moreover, considering the highly heterogeneous nature of the MC populations residing in the lung, 26 it cannot be excluded that beneficial and detrimental activities of MCs can be attributed to phenotypically distinct MC populations.
Our data show that HDM treatment of mice resulted in increased airway reactivity, this being in line with previous reports using similar HDM-based models. 10, 11, 27 Moreover, we found evidence suggesting that the presence of chymase protects towards excessive airway reactivity at high doses of metacholine. Mechanistically, we found that the excessive airway reactivity in mMCP-4 À / À mice was accompanied by a much more profound thickening of the ASM layer as compared with WT mice, ASM hypertrophy being one of the key components of airway hyperresponsiveness. 28 Hence, a likely explanation for the elevated airway reactivity in mMCP-4 À / À mice is that chymase prevents an expansion of the ASM layer. In addition to the effects of chymase on airway reactivity, an important finding was that the absence of chymase led to an excessive airway inflammation. In particular, chymase was shown to protect from excessive eosinophilia. Hence, the presence of chymase protects from extensive manifestations of two of the hallmark features of asthma-increased airway reactivity and eosinophilia.
To search for mechanisms operative in the protective effect of chymase in airway responses, we hypothesized that chymase may act by proteolytic effects on pro-inflammatory cytokines. This hypothesis was based on previous studies, mainly from in vitro settings, showing that chymase can cleave a variety of cytokines (reviewed in Pejler et al.
3 ). Indeed, we show that HDM treatment resulted in a profound accumulation of IL-33 in the lung tissue of animals lacking mMCP-4, whereas no corresponding IL-33 accumulation was seen in WT mice. A likely explanation for this finding is that chymase controls IL-33 levels by proteolytic degradation of the cytokine. In support of this, WT MCs were shown to degrade IL-33 efficiently in vitro, whereas MCs lacking À / À peritoneal cell-derived mast cells were subjected to FceRI crosslinking (immunoglobulin E/antigen (IgE/Ag)) in the presence of exogenous IL-33. Experiments were performed with or without addition of a serine protease inhibitor (Pefabloc SC). IL-33 levels in the supernatants were measured after 20, 50, and 120 min using enzyme-linked immunosorbent assay. Data are shown as percentage of residual IL-33 compared with time ¼ 0; expressed as means ± s.e.m. (n ¼ 3). *Po0.05; **Po0.01; ***Po0.001 (Student's t-test). (b) mMCP-4 or human chymase were incubated with murine or human IL-33, respectively. At the time points indicated, reactions were terminated followed by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and staining with Coomassie. As a control to verify that IL-33 was reduced through proteolysis, mMCP-4 was incubated for 60 min with a general serine protease inhibitor (Pefabloc SC; final concentration 2 mM) before experiments.
mMCP-4 had a reduced capacity for IL-33 degradation, and we also showed that purified chymase of both murine and human origin efficiently degrades IL-33. Interestingly, recent studies have strongly implicated IL-33 as a key cytokine regulating Th2 responses. For example, intraperitoneal administration of IL-33 in mice results in a Th2 cytokine response and increased levels of blood eosinophils, as well as enhanced IgE-levels. [29] [30] [31] [32] Further, IL-33 has been linked to asthma due to its ability to provoke airway reactivity when administered in vivo 33 and is emerging as a potential target in the treatment of asthma. 34, 35 Together, we may thus propose that the protective effect of chymase on airway inflammation and on airway reactivity may be explained, at least partly, by effects on IL-33. Considering the central importance of IL-13 for allergic lung responses, it was somewhat unexpected that HDM treatment did not lead to increased tissue levels of IL-13. However, earlier studies have shown that an increase in IL-13 is only seen at early time points after initiation of the immunization protocol, 10 whereas we used a longer immunization scheme.
In non-activated MCs, chymase is stored within the secretory granules. To have an impact on any extracellular process, it thus needs to become exocytosed. During an allergic response, this will most likely be accomplished by crosslinking of antigen-specific IgE present on the MC surface. Accordingly, chymase is expected to have effects predominantly at the late inflammatory phase of the response towards HDM immunization, i.e., at a stage when HDM-specific IgE is prevalent. However, an intriguing finding in this investigation was that the absence of chymase resulted in increased serum IgE levels in response to HDM treatment and also in an exaggerated cytokine response of HDM-restimulated splenocytes. This indicates that chymase, in addition to influencing the inflammatory phase, also can have an impact on the sensitization stage of the disease. Further, this implies that chymase may become exocytosed by mechanisms independent of HDM-specific IgE. Indeed, we show that HDM extract has direct effects on MCs, leading to exocytosis of chymase. Potentially, chymase exocytosed upon direct contact of MCs with HDM may thus have the ability to affect the initial immune response to HDM, e.g., by acting proteolytically on IL-33 or, alternatively, directly on antigens present in the HDM extract. Importantly, although our data indicate that chymase is exocytosed through a direct effect of HDM extracts on MCs, we cannot exclude that additional mechanisms of early chymase exocytosis are operative in vivo, e.g., mediated by effects of cytokines, such as IL-33. 36 In summary, this study suggests that mMCP-4 is released by MCs in the local environment in response to HDM (Figure 7) . mMCP-4, which is stored as an active enzyme, can thus directly act in the inflammatory process and can also be involved in regulating the initial immune response to HDM antigens. The results presented here suggest that IL-33 is one of the prime targets for exocytosed chymase and that the absence of chymase leads to an excessive accumulation of IL-33 and thereby to exaggerated airway responses. À / À mice 5 backcrossed to the C57BL/6J strain for 13 generations and WT littermate controls were used. Eight-week-old male mice were lightly anesthetized with isoflurane and instilled intranasally with 3 mg HDM extract from species Dermatophagoides farinae (Greer Laboratories, Lenoir, NC), dissolved in 30 ml PBS, on days 1, 4, 8, 11, 15, and 18 . Control mice were instilled with PBS intranasally. All animal experiments were approved by the local ethical committee.
Measurement of airway reactivity. Forty-eight hours after the final instillation, mice were anesthetized with pentobarbital sodium (50 mg kg À 1 ; Sigma-Aldrich, St Louis, MO), tracheostomized, and intubated to a small animal ventilator (FinePointe, Buxco, Winchester, UK). Mice were mechanically ventilated at 160 breaths min À 1 with a tidal volume of 0.25 ml. Before measurements, mice were shortly ventilated to reach an acclimatization baseline. Lung function was assessed with a dose-response curve to increasing doses of aerosolized methacholine (2-16 mg ml À 1 ; Sigma-Aldrich) via the tracheal cannula. Lung resistance (R L ) is shown as percentage of change from baseline. Results were pooled from five separate and matched experiments.
BAL and lung tissue sampling and homogenization. BAL fluid was collected as previously described. 37 Cytospin slides were prepared and the percentage of leukocyte populations was determined after May Grünwald/Giemsa staining. For cytokine measurements, the right lung lobes were frozen on dry ice and stored at À 70 1C. Lung tissue was homogenized in HBSS (Hank's balanced salt solution) containing protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) at a concentration of 50 mg lung tissue per ml buffer. The homogenates were centrifuged at 800 Â g at 4 1C for 8 min, and supernatants were collected for cytokine measurements using enzyme-linked immunosorbent assay (ELISA).
Histology. The left lung lobe was preserved in 4% paraformaldehyde, paraffin-embedded, sectioned and stained with hematoxylin and eosin (H&E) as previously described. 6, 38 The extent of tissue inflammation around the primary bronchi was evaluated by blinded counting of eosinophils. In addition, broncho-vascular units containing cell infiltration were counted, and results are shown as percentage per individual. Thickness of the ASM layer around similar size bronchi (diameter range 500-650 mm) was measured with a Nikon Microphot-FXA microscope using the Â 10 objective lens (Bergström Instrument AB, Stockholm, Sweden) and Eclipse Net software (version 1.20, developed by Laboratory Imaging, Prague, Czech Republic) on H&E-stained sections. ASM layer thickness was measured every 30 mm around the primary bronchi, and average thickness was calculated. For periodic acid-Schiff staining, slides were deparaffinized, hydrated, oxidized in 0.05% periodic acid for 5 min, washed in H 2 O, stained with Schiff's reagent (Sigma-Aldrich) for 30 min, washed in H 2 O for 3 min, and counterstained with Mayer's hematoxylin for 30 s. MCs were identified by toluidine blue staining. 39 Restimulation of splenocytes. Restimulation of splenocytes was performed as previously described. 40 Forty-eight hours after the last intranasal instillation, the spleens were collected and mechanically dispersed followed by passing of the tissue through a nylon filter. Red blood cells were eliminated by lysis. Splenocytes were seeded (4 Â 10 6 cells ml À 1 , 1 ml per well) into a 24-well plate and were stimulated with 20 mg ml À 1 HDM extract for 72 h. ELISA was used to measure release of cytokines into the cell culture supernatant.
Generation and degranulation of PCMCs. PCMCs were established according to a previously described protocol. 12 IgE anti-TNP (antitrinitrophenyl; BD Biosciences Pharmingen, Stockholm, Sweden) was added to 1 Â 10 6 PCMCs at 1 mg ml À 1 followed by incubation overnight at 37 1C. Cells were washed three times and resuspended in Dulbecco's modified Eagle's medium supplemented as described above. OVA-TNP was added (0.4 mg ml À 1 final concentration). For calcium ionophore-mediated degranulation, A23187 (Sigma-Aldrich) was added (2 mM final concentration). Mouse recombinant IL-33 (PeproTech, London, UK) was added at 2 ng ml À 1 immediately after stimulation with IgE anti-TNP. To block serine protease activity, 1 mM Pefabloc SC (Pentapharm LTD, Basel, Switzerland) was added 10 min before MC activation. Supernatants were collected 0, 20, 40, and 60 min after stimulation.
Chymase activity. PCMCs were washed twice and resuspended in HBSS at a density of 1 Â 10 6 cells ml À 1 and placed in triplicates (100 ml per well) in a 96-well plate. HDM extract was added at a final concentration of 200 mg ml À 1 . A23187 (2 mM final concentration) was used as a positive control for PCMC degranulation. Chymase-like activity was measured using a fluorogenic substrate (Suc-Ala-Ala-ProPhe-AMC), according to the manufacturer's instructions (Bachem, Weil am Rhein, Germany). The reaction was allowed to proceed for 2 h in room temperature, and fluorescence was measured at 360 nm (excitation) and 460 nm (emission) every 10 min using a FARCyte microplate reader (Amersham Biosciences, Uppsala, Sweden). 
